E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Pulmonary hypertension in patients with interstitial lung disease. Specifically this trial looks at patients who have mild pulmonary hypertension, or are in an at-risk group to developing pulmonary hypertension, in the context of their interstitial lung disease. The interstitial lung diseases addressed include idiopathic pulmonary fibrosis and non-specific interstitial pneumonitis. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10064911 |
E.1.2 | Term | Pulmonary arterial hypertension |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To efficacy of bosentan in preventing the development of established pulmonary hypertension in patients with fibrosing lung disease considered at-risk of developing pulmonary hypertension.
The primary endpoint is the change in resting pulmonary vascular resistance from baseline to week 52. |
|
E.2.2 | Secondary objectives of the trial |
To assess the ability of bosentan to effect exercise capacity, and pulmonary blood flow, lung function and quality of life in patients with fibrosing lung disease at risk of developing pulmonary arterial hypertension.
The secondary endpoints are changes from baseline to week 52 in the followin parameters: 1. Exercise capacity as measured by the 6-minute walk test, and Borg dyspnoea scale 2. Pulmonary blood flow 3. Lung function (DLco% predicted, FVC % predicted, composite physiological index) 4. Right heart catheter data (mean pulmonary arterial pressure, systolic pulmonary arterial pressure, mean right atrial pressure, systemic vascular resistance and cardiac index) 5. Quality of life as measured by teh CAMPHOR questionnaire 6. WHO functional class 7. Time to decline (Death, transplanation, hospitalisation , supplemental oxygen, disease progression). 8. Right ventricular mass (on cardiac MRI) 9. Brain natriuretic peptide |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patients >=18yrs, <80yrs
2. Patients with Idiopathic Pulmonary Fibrosis or fibrotic Non-Specific Pneumonitis according to ATS/ERS criteria.
3. Patients with mild pulmonary hypertension or at risk of developing pulmonary hypertension (Pre-PH), as defined by: o Mild-PH: RHC: mean PAH 25-35mmHg, PCWP<15mmHg, and 6-minute walk test oxygen desaturation <89% o Pre-PH: RHC: mean PAP <25mmHg, PCWP<15mmHg, 6-minute walk test oxygen desaturation <89%
4. Patients providing written informed consent. |
|
E.4 | Principal exclusion criteria |
1. Patients <18, >80yrs.
2. Patients with unstable disease, or an acute exacerbation of their underlying fibrotic lung disease.
3. Patients with significant other organ co-morbidity including hepatic or renal impairment.
4. Patients with systolic BP < 85mmHg
5. Patients with other conditions that may affect the ability to perform a 6-minute walk test.
6. Patients unable to provide informed consent and comply with the patient protocol.
7. Patients receiving excluded medications (including: epoprostenol, or prostacyclin analogues, phosphodiesterase inhibitors, other endothelin receptor antagonists, drugs with potential interaction with bosentan such as glibenclamide, fluconazole, cyclosporin A, or tacrolimus, and other invesgational agents).
8. Patients with planned surgical intervention during the study period.
9. Pregnant patients
10. Patients with resting oxygen saturation <90%
11. Patients with clinically overt ischaemic heart disease
12. Patients with predominant emphysema on CT scan (in excess of interstitial changes)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the change in resting pulmonary vascular resistance from baseline to week 52 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Information not present in EudraCT |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Information not present in EudraCT |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Information not present in EudraCT |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |